Cargando…
Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis
BACKGROUND: This meta-analysis was conducted to investigate the effects of incretin-based therapeutic agents, including the latest agent tirzepatide, on renal outcomes in patients with type 2 diabetes. METHODS: MEDLINE (via PubMed) and Cochrane databases were searched for studies involving incretin-...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009293/ https://www.ncbi.nlm.nih.gov/pubmed/36923991 http://dx.doi.org/10.1016/j.metop.2023.100236 |
_version_ | 1784905952520044544 |
---|---|
author | Mima, Akira Gotoda, Hidemasa Lee, Rina Murakami, Ami Akai, Ryosuke Lee, Shinji |
author_facet | Mima, Akira Gotoda, Hidemasa Lee, Rina Murakami, Ami Akai, Ryosuke Lee, Shinji |
author_sort | Mima, Akira |
collection | PubMed |
description | BACKGROUND: This meta-analysis was conducted to investigate the effects of incretin-based therapeutic agents, including the latest agent tirzepatide, on renal outcomes in patients with type 2 diabetes. METHODS: MEDLINE (via PubMed) and Cochrane databases were searched for studies involving incretin-based therapeutic agents up to July 2022. Randomized and controlled trials comparing incretin-based therapeutic agents with placebo or other antidiabetic agents, and reporting renal outcomes were selected. The inclusion criteria were items related to the effects on albuminuria and the kidney-specific composite outcomes. A network meta-analysis was conducted to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Twelve trials consisting of 75,346 participants were included in this meta-analysis. Glucagon-like peptide-1 (GLP-1) receptor agonists reduced the risk of the kidney-specific composite outcome by 21% (HR 0.79, 95% CI 0.75–0.85), and worsening albuminuria by 24% (HR 0.76, 95% CI 0.71–0.82). In particular, the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide remarkably reduced the risk of the kidney-specific composite outcome by 45% (HR 0.55, 95% CI 0.40–0.77), and worsening albuminuria by 62% (HR 0.38, 95% CI 0.24–0.61). CONCLUSIONS: Among incretin-based therapeutic agents, tirzepatide was associated with a significantly reduced risk of diabetic kidney disease. |
format | Online Article Text |
id | pubmed-10009293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-100092932023-03-14 Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis Mima, Akira Gotoda, Hidemasa Lee, Rina Murakami, Ami Akai, Ryosuke Lee, Shinji Metabol Open Original Research Paper BACKGROUND: This meta-analysis was conducted to investigate the effects of incretin-based therapeutic agents, including the latest agent tirzepatide, on renal outcomes in patients with type 2 diabetes. METHODS: MEDLINE (via PubMed) and Cochrane databases were searched for studies involving incretin-based therapeutic agents up to July 2022. Randomized and controlled trials comparing incretin-based therapeutic agents with placebo or other antidiabetic agents, and reporting renal outcomes were selected. The inclusion criteria were items related to the effects on albuminuria and the kidney-specific composite outcomes. A network meta-analysis was conducted to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Twelve trials consisting of 75,346 participants were included in this meta-analysis. Glucagon-like peptide-1 (GLP-1) receptor agonists reduced the risk of the kidney-specific composite outcome by 21% (HR 0.79, 95% CI 0.75–0.85), and worsening albuminuria by 24% (HR 0.76, 95% CI 0.71–0.82). In particular, the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide remarkably reduced the risk of the kidney-specific composite outcome by 45% (HR 0.55, 95% CI 0.40–0.77), and worsening albuminuria by 62% (HR 0.38, 95% CI 0.24–0.61). CONCLUSIONS: Among incretin-based therapeutic agents, tirzepatide was associated with a significantly reduced risk of diabetic kidney disease. Elsevier 2023-02-24 /pmc/articles/PMC10009293/ /pubmed/36923991 http://dx.doi.org/10.1016/j.metop.2023.100236 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Paper Mima, Akira Gotoda, Hidemasa Lee, Rina Murakami, Ami Akai, Ryosuke Lee, Shinji Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis |
title | Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis |
title_full | Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis |
title_fullStr | Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis |
title_full_unstemmed | Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis |
title_short | Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis |
title_sort | effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: a systemic review and meta-analysis |
topic | Original Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009293/ https://www.ncbi.nlm.nih.gov/pubmed/36923991 http://dx.doi.org/10.1016/j.metop.2023.100236 |
work_keys_str_mv | AT mimaakira effectsofincretinbasedtherapeuticagentsincludingtirzepatideonrenaloutcomesinpatientswithtype2diabetesasystemicreviewandmetaanalysis AT gotodahidemasa effectsofincretinbasedtherapeuticagentsincludingtirzepatideonrenaloutcomesinpatientswithtype2diabetesasystemicreviewandmetaanalysis AT leerina effectsofincretinbasedtherapeuticagentsincludingtirzepatideonrenaloutcomesinpatientswithtype2diabetesasystemicreviewandmetaanalysis AT murakamiami effectsofincretinbasedtherapeuticagentsincludingtirzepatideonrenaloutcomesinpatientswithtype2diabetesasystemicreviewandmetaanalysis AT akairyosuke effectsofincretinbasedtherapeuticagentsincludingtirzepatideonrenaloutcomesinpatientswithtype2diabetesasystemicreviewandmetaanalysis AT leeshinji effectsofincretinbasedtherapeuticagentsincludingtirzepatideonrenaloutcomesinpatientswithtype2diabetesasystemicreviewandmetaanalysis |